There Are No Validated Serologic "IBS Markers" for Diagnosis
The AGA explicitly makes no recommendation for currently available serologic tests to diagnose IBS due to insufficient diagnostic accuracy—IBS remains a clinical diagnosis based on symptoms, not laboratory markers 1.
What Tests Should Actually Be Ordered
The goal is to exclude other diagnoses, not to confirm IBS. Based on the most recent guidelines, here's the algorithmic approach:
Mandatory Initial Testing (All Patients)
- Full blood count
- C-reactive protein (CRP) or ESR
- Celiac serology: IgA tissue transglutaminase (IgA-tTG) PLUS a second test for IgA deficiency (IgG-tTG or IgG/IgA deaminated gliadin peptides if IgA-deficient) 1, 2
- Fecal calprotectin (if age <45 years with diarrhea) 2, 3
Conditional Testing Based on Clinical Features
For IBS-D with atypical features (nocturnal diarrhea, prior cholecystectomy):
- 23-seleno-25-homotaurocholic acid (SeHCAT) scanning OR serum 7α-hydroxy-4-cholesten-3-one to exclude bile acid malabsorption 2
- If unavailable, consider empiric trial of bile acid binders 1
Avoid these tests:
- ESR/CRP for IBD screening (conditional recommendation against) 1
- Stool ova and parasites (except Giardia testing, which IS recommended) 1
- IgG food antibody panels (strong recommendation against) 2
- Hydrogen breath tests for lactose or SIBO (no role in routine assessment) 4
Why "IBS Markers" Don't Work
The commercially available serologic tests (anti-cytolethal distending toxin B and anti-vinculin antibodies) have dismal sensitivity of only 20-40% despite 90% specificity 1. This means they miss 60-80% of IBS cases, making them clinically useless for routine diagnosis 5.
Recent research shows IBS patients do have elevated inflammatory markers (TNF-α, IL-6, IFN-γ) and higher fecal calprotectin than healthy controls 6, but these overlap significantly with other conditions and cannot reliably diagnose IBS.
The Bottom Line
Make a positive clinical diagnosis based on Rome IV or NICE criteria (abdominal pain + altered bowel habit for ≥6 months), then use limited testing only to exclude organic disease 2, 4. The number needed to diagnose with routine biomarkers is 34—meaning you'll spend approximately €4,900 per non-IBS diagnosis found 7.
Critical Pitfall to Avoid
Do not pursue exhaustive testing or colonoscopy in patients meeting IBS criteria without alarm features or abnormal initial tests—this is costly, counterproductive, and reinforces illness behavior 4, 7.